BR112013010834A2 - polipeptídeos fator ix modificados e usos dos mesmos - Google Patents

polipeptídeos fator ix modificados e usos dos mesmos

Info

Publication number
BR112013010834A2
BR112013010834A2 BR112013010834A BR112013010834A BR112013010834A2 BR 112013010834 A2 BR112013010834 A2 BR 112013010834A2 BR 112013010834 A BR112013010834 A BR 112013010834A BR 112013010834 A BR112013010834 A BR 112013010834A BR 112013010834 A2 BR112013010834 A2 BR 112013010834A2
Authority
BR
Brazil
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Application number
BR112013010834A
Other languages
English (en)
Other versions
BR112013010834B1 (pt
Inventor
Thanos Christopher
L Madison Edwin
Ellsworth Blouse Grant
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of BR112013010834A2 publication Critical patent/BR112013010834A2/pt
Publication of BR112013010834B1 publication Critical patent/BR112013010834B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

polipeptídeos fator ix modificados e usos dos mesmos. polipeptídeos fator ix modificados e usos dos mesmos.
BR112013010834A 2010-11-03 2011-11-03 polipeptídeos de fator ix modificados e usos dos mesmos BR112013010834B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45629810P 2010-11-03 2010-11-03
PCT/US2011/059233 WO2012061654A1 (en) 2010-11-03 2011-11-03 Modified factor ix polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
BR112013010834A2 true BR112013010834A2 (pt) 2017-10-24
BR112013010834B1 BR112013010834B1 (pt) 2021-08-03

Family

ID=44936595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010834A BR112013010834B1 (pt) 2010-11-03 2011-11-03 polipeptídeos de fator ix modificados e usos dos mesmos

Country Status (17)

Country Link
US (4) US8778870B2 (pt)
EP (2) EP2635677B1 (pt)
JP (2) JP2013545457A (pt)
KR (2) KR101790589B1 (pt)
CN (1) CN103282491B (pt)
AU (1) AU2011323295B2 (pt)
BR (1) BR112013010834B1 (pt)
CA (2) CA3129054A1 (pt)
DK (2) DK2635677T3 (pt)
ES (1) ES2782078T3 (pt)
MX (2) MX365396B (pt)
MY (2) MY162576A (pt)
NZ (2) NZ707439A (pt)
SG (2) SG190089A1 (pt)
TW (2) TWI595004B (pt)
WO (1) WO2012061654A1 (pt)
ZA (1) ZA201303134B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5376747B2 (ja) * 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
ATE534734T1 (de) 2004-04-12 2011-12-15 Catalyst Biosciences Inc Spaltung von vegf und vegf-rezeptoren durch wildtyp- und mutante mt-sp1
NZ595193A (en) 2005-10-21 2013-09-27 Catalyst Biosciences Inc Modified Proteases That Inhibit Complement Activation
EP2046951B1 (en) 2006-07-05 2011-10-26 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thererby
EP2147096B1 (en) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP3581650B1 (en) 2008-09-15 2022-12-28 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
JP6454643B2 (ja) 2012-10-26 2019-01-16 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ 血友病の肝臓指向性遺伝子治療のためのベクター並びにその方法及び使用
EP3513802B1 (en) * 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
JP2015536148A (ja) * 2012-11-20 2015-12-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変第ｉｘ因子タンパク質についての方法および組成物
WO2014099850A1 (en) * 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. FACTOR IXa 318R/A MUTANT
CN103060366A (zh) * 2012-12-25 2013-04-24 武汉科技大学 人凝血因子ⅸ突变体毕赤酵母表达载体及构建方法和应用
EP2881463A1 (en) * 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
JP6978407B2 (ja) * 2015-08-06 2021-12-08 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｇｌｐ−１及び代謝性疾患を治療するための組成物におけるその使用
CN109789181A (zh) * 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
CN116355883A (zh) * 2016-10-14 2023-06-30 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
US20200109390A1 (en) * 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
KR102551733B1 (ko) * 2017-05-22 2023-07-06 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
US11491212B1 (en) * 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201817810D0 (en) * 2018-10-31 2018-12-19 Ucl Business Plc Modified factor IX polypeptides
US11596671B2 (en) 2019-02-01 2023-03-07 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
AU2020242945A1 (en) * 2019-03-19 2021-10-14 CSL Innovation Pty Ltd Factor IX variants and uses thereof in therapy
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
WO2021154414A2 (en) * 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
WO2023224992A2 (en) * 2022-05-16 2023-11-23 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells
WO2024077335A1 (en) * 2022-10-10 2024-04-18 CSL Innovation Pty Ltd Factor ix variant polypeptides for administration to soft tissue

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
EP0521873B1 (en) 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
JP2001522230A (ja) 1997-02-14 2001-11-13 アメリカン・レツド・クロス トランスジェニック動物***組織における活性ヒト第▲ｉｘ▼因子の発現
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
US7419949B2 (en) 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
RU2004110239A (ru) * 2001-09-04 2005-10-20 Мерк Патент ГмбХ (DE) Модифицированный фактор ix
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
JP5376747B2 (ja) 2002-10-02 2013-12-25 カタリスト バイオサイエンシーズ， インコーポレイテッド 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法
ES2911435T3 (es) 2003-02-26 2022-05-19 Nektar Therapeutics Conjugados de polímero-resto de Factor VIII
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7771996B2 (en) 2003-03-20 2010-08-10 Bayer Healthcare Llc FVII or FVIIa variants
EP1620539A4 (en) 2003-05-05 2007-09-26 Monsanto Technology Llc TRANSGENIC PLANTS WITH INCREASED GLYCIN BETAIN
PL2077121T3 (pl) 2003-05-06 2011-07-29 Syntonix Pharmaceuticals Inc Białka chimeryczne o strukturze czynnik krzepliwości krwi VII-FC do leczenia zaburzenia hemostatycznego
BRPI0411650A (pt) 2003-06-19 2006-08-08 Maxygen Holdings Ltd variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável
JP2007509843A (ja) 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ＶＩＩ／ＶＩＩａ因子活性を有するハイブリッド分子
ATE534734T1 (de) 2004-04-12 2011-12-15 Catalyst Biosciences Inc Spaltung von vegf und vegf-rezeptoren durch wildtyp- und mutante mt-sp1
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20080188400A1 (en) 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
AU2006280932A1 (en) 2005-08-19 2007-02-22 Novo Nordisk A/S Glycopegylated factor VII and factor Vila
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
NZ595193A (en) 2005-10-21 2013-09-27 Catalyst Biosciences Inc Modified Proteases That Inhibit Complement Activation
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
EP2650305B1 (en) 2006-03-24 2024-05-08 Bioverativ Therapeutics Inc. PC5 as a factor IX propeptide processing enzyme
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US8741096B2 (en) 2006-06-29 2014-06-03 Wonik Ips Co., Ltd. Apparatus for semiconductor processing
EP2046951B1 (en) 2006-07-05 2011-10-26 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thererby
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8507653B2 (en) 2006-12-27 2013-08-13 Nektar Therapeutics Factor IX moiety-polymer conjugates having a releasable linkage
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP1952822A1 (en) 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
AU2008209986B2 (en) 2007-02-01 2012-11-08 Baxter Healthcare S.A. FVIII-independent FIX-mutant proteins for hemophilia A treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
EP2147096B1 (en) 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
WO2009051717A2 (en) 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
MX2010011345A (es) * 2008-04-16 2011-02-23 Bayer Healthcare Llc Polipeptidos modificados del factor ix y usos de los mismos.
KR20110015551A (ko) 2008-04-16 2011-02-16 바이엘 헬스케어 엘엘씨 제ｉｘ인자의 부위-지정 변형
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP3581650B1 (en) 2008-09-15 2022-12-28 uniQure biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
EP2445513B1 (en) 2009-06-25 2014-08-27 The University of North Carolina At Chapel Hill Chimeric factor vii molecules
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.

Also Published As

Publication number Publication date
AU2011323295B2 (en) 2015-05-28
KR101790589B1 (ko) 2017-10-27
EP2635677B1 (en) 2020-01-01
JP6027221B2 (ja) 2016-11-16
WO2012061654A1 (en) 2012-05-10
CA3129054A1 (en) 2012-05-10
ZA201303134B (en) 2018-12-19
KR20130132833A (ko) 2013-12-05
BR112013010834B1 (pt) 2021-08-03
US20130177541A9 (en) 2013-07-11
US10982203B2 (en) 2021-04-20
MY192475A (en) 2022-08-23
DK3663399T3 (da) 2022-03-21
MX345314B (es) 2017-01-23
US20160201047A1 (en) 2016-07-14
MY162576A (en) 2017-06-30
NZ707439A (en) 2017-03-31
US20140322191A1 (en) 2014-10-30
MX365396B (es) 2019-05-31
CA2816325A1 (en) 2012-05-10
CA2816325C (en) 2022-08-23
EP2635677A1 (en) 2013-09-11
US20120308540A1 (en) 2012-12-06
DK2635677T3 (da) 2020-04-06
TW201630932A (zh) 2016-09-01
AU2011323295A1 (en) 2013-05-02
US8778870B2 (en) 2014-07-15
CN103282491B (zh) 2016-08-24
SG190089A1 (en) 2013-06-28
JP2013545457A (ja) 2013-12-26
EP3663399A1 (en) 2020-06-10
MX2013004828A (es) 2013-08-29
TWI557135B (zh) 2016-11-11
SG10201510704PA (en) 2016-01-28
US9328339B2 (en) 2016-05-03
KR20170054545A (ko) 2017-05-17
KR101841906B1 (ko) 2018-03-26
NZ609959A (en) 2015-05-29
EP3663399B1 (en) 2021-12-22
JP2016116519A (ja) 2016-06-30
CN103282491A (zh) 2013-09-04
ES2782078T3 (es) 2020-09-10
US20210230570A1 (en) 2021-07-29
TW201242975A (en) 2012-11-01
TWI595004B (zh) 2017-08-11

Similar Documents

Publication Publication Date Title
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
CY1122101T1 (el) Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων
BR112015001628A2 (pt) polipeptídeos de fator x modificados e uso dos mesmos
BR112013029163A2 (pt) modulação quinase e indicações dos mesmos
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK3346008T3 (da) Rekombinante mikroorganismer og anvendelser deraf
BR112013021524A2 (pt) micro-organismos recombinantes e usos dos mesmos
BRPI0910702A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
BR112013011803A2 (pt) método de controle e terminal portátil que suporta o mesmo
BR112014005502A2 (pt) adesivos contendo proteínas, e fabricação e uso dos mesmos
DK2536830T3 (da) Polypeptider
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK3459564T3 (da) Plasmakallikreinbindende proteiner
BR112012002072A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
BR112013013663A2 (pt) ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização
DK3115372T3 (da) Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
DK2571624T3 (da) Multifysisk brændstofforstøver og fremgangsmåder
BR112013014235A2 (pt) anticorpos anti-ccr4 e usos dos mesmos
BR112013002042A2 (pt) inibidor de tirosinase polipeptídico
BR112013028251A2 (pt) polipeptídeo
IT1398438B1 (it) Dispositivo di premacinazione e relativo procedimento
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
DE11786796T8 (de) Antigenpeptid und verwendung davon

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: GC BIOPHARMA CORP. (KR)